Oncology Articles

Nab-Paclitaxel/Carboplatin Doublet Superior in Phase II tnAcity Trial
The combination of nab-paclitaxel and carboplatin reduced the risk of progression or death by 40% compared with 2 other chemotherapy doublets as a frontline therapy for patients with metastatic triple-negative breast cancer.
Pembrolizumab Shows Durable Responses in Heavily Pretreated TNBC
Treatment with pembrolizumab continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.
Pembrolizumab/Eribulin Combo Shows Promise for TNBC
The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.
FDA Grants Priority Review to Durvalumab in Bladder Cancer
The FDA has granted a priority review to a biologics license application for the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum?based chemotherapy.
IBM's Watson Achieves High Concordance in Tumor Board Test
The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
AI Therapy May Pose Cardiovascular Risk for Breast Cancer Survivors
Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.
Women With Menopausal Symptoms Less Likely to Adhere to Breast Cancer Prevention Treatment
Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.
Ribociclib Shows Consistent Benefit in Advanced Breast Cancer Subgroups
A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.
Sacituzumab Govitecan Elicits Durable Responses for Pretreated TNBC
Treatment with sacituzumab govitecan was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer.
More Evidence That Scalp Cooling Devices Work, Especially During Taxane-Based Chemotherapy
Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.
Publication Bottom Border
Border Publication